PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.47%
Both companies show declining cash positions (-7.47% vs AVXL's -0.63%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.47%
Cash + STI yoy ≥ 1.5x AVXL's -0.63%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.14%
≥ 1.5x AVXL's -2.92%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-20.34%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.34%
Below half of AVXL's -100.00%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-7.25%
≥ 1.5x AVXL's -2.92%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-4.95%
Above 1.5x AVXL's -2.22%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-36.48%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-627.15%
Both AVXL and the company show zero Deferred Revenue (Current) Growth.
-89.58%
Higher Other Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
-16.33%
Above 1.5x AVXL's -2.50%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-33.33%
Above 1.5x AVXL's -9.55%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-16.34%
Above 1.5x AVXL's -2.50%. Michael Burry sees a potential leverage warning sign.
No Data
No Data available this quarter, please select a different quarter.
-2.01%
Below half AVXL's -5.51%. Michael Burry suspects major net losses or high dividends vs. competitor.
100.00%
Less than half of AVXL's 200.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to AVXL's zero value, indicating worse performance.
-6.40%
≥ 1.5x AVXL's -2.95%. David Dodd sees stronger capital base growth than competitor.
-7.25%
≥ 1.5x AVXL's -2.92%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
-36.45%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
7.35%
Above 1.5x AVXL's 0.63%. Michael Burry sees a major gap in net debt growth. Check coverage and liquidity.